AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28671553 — intervention group
Group type: EXPERIMENTAL
Intervention: High HBV viral load (>6 log IU/ml) patients in ETV group
Number of subjects: 17
Study 26987021 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI)
Number of subjects: 9
Study 26987021 — intervention group
Group type: EXPERIMENTAL
Intervention: High polyphenolic cocoa (HP)
Number of subjects: 9
Study 26987021 — intervention group
Group type: EXPERIMENTAL
Intervention: WPI and HP beverages
Number of subjects: 9
Study 26987021 — intervention group
Group type: COMPARATOR
Intervention: All beverages
Number of subjects: 9
Study 24937975 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture performed off-site before and after embryo transfer (n = 57)
Number of subjects: 113
Study 24937975 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group, n = 56)
Number of subjects: 113
Study 22252354 — intervention group
Group type: EXPERIMENTAL
Intervention: GAA supplementation at 0.6 g/kg
Number of subjects: 768
Study 22252354 — intervention group
Group type: EXPERIMENTAL
Intervention: GAA supplementation at 1.2 g/kg
Number of subjects: 768
Study 22252354 — intervention group
Group type: EXPERIMENTAL
Intervention: GAA diets
Number of subjects: 768
Study 22252354 — intervention group
Group type: EXPERIMENTAL
Intervention: GAA-fed birds
Number of subjects: 768
Study 22252354 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g/kg GAA
Number of subjects: 768
Study 20635660 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-reinforced composite (FRC)
Number of subjects: 60
Study 20635660 — intervention group
Group type: COMPARATOR
Intervention: Multistrand stainless steel wire (MSSW)
Number of subjects: 60
Study 16938155 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 10 mbar
Number of subjects: 28
Study 16938155 — intervention group
Group type: COMPARATOR
Intervention: PEEP 5 mbar (control)
Number of subjects: 28
Study 16912577 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity smoking cessation intervention
Number of subjects: 117
Study 16912577 — intervention group
Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 117
Study 16912577 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 117
Study 16912577 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention cohort
Number of subjects: 117
Study 16912577 — intervention group
Group type: COMPARATOR
Intervention: Control cohort
Number of subjects: 117
Study 12858199 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan, melphalan and thiotepa (Bu/Mel/T)
Number of subjects: 92
Study 12858199 — intervention group
Group type: COMPARATOR
Intervention: Total body irradiation, cyclophosphamide and etoposide (TBI/CY/E)
Number of subjects: 92
Study 10577993 — intervention group
Group type: EXPERIMENTAL
Intervention: -344C allele in CYP11B2 gene
Number of subjects: 411
Study 10577993 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 411
Study 10577993 — intervention group
Group type: EXPERIMENTAL
Intervention: -344CC homozygous smokers
Number of subjects: 411
Study 10577993 — intervention group
Group type: EXPERIMENTAL
Intervention: -344TT homozygotes
Number of subjects: 411
Study 10577993 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased HDL cholesterol level
Number of subjects: 411
Study 8768511 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure in vivo followed by cognitive therapy
Number of subjects: 26
Study 8768511 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy followed by exposure in vivo
Number of subjects: 26
Study 8768511 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral treatment integrating both strategies from the start
Number of subjects: 26
Study 8768511 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 26
Study 8768511 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-exposure treatment
Number of subjects: 26
Study 1716340 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMACE-CytaBOM (P-C)
Number of subjects: 179
Study 1716340 — intervention group
Group type: COMPARATOR
Intervention: MACOP-B (M-B)
Number of subjects: 179
Study 6981695 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled cephaloridine
Number of subjects: 47
Study 6981695 — intervention group
Group type: COMPARATOR
Intervention: No inhaled antibiotic (Control)
Number of subjects: 47
Study 30451538 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino Acids (AAs) supplementation
Number of subjects: 25
Study 30451538 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric glucose (Control)
Number of subjects: 25
Study 28277415 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated Hypothermia (32-35°C)
Number of subjects: 386
Study 28277415 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 386
Study 25943670 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal cooling (ICE, 7.5 g/kg ice slurry ingestion)
Number of subjects: 12
Study 25943670 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-methods external cooling (EXT, cold towels, forearm immersion, ice vest, and cooling shorts)
Number of subjects: 12
Study 25943670 — intervention group
Group type: COMPARATOR
Intervention: Internal cooling (ICE)
Number of subjects: 12
Study 25943670 — intervention group
Group type: COMPARATOR
Intervention: Mixed-methods external cooling (EXT)
Number of subjects: 12
Study 25943670 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling (ICE and EXT)
Number of subjects: 12
Study 25943670 — intervention group
Group type: COMPARATOR
Intervention: Cooling (EXT)
Number of subjects: 12
Study 25943670 — intervention group
Group type: COMPARATOR
Intervention: Cooling (ICE)
Number of subjects: 12
Study 24731903 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple moxibustion (n=15) for 30min
Number of subjects: 30
Study 24731903 — intervention group
Group type: COMPARATOR
Intervention: Single moxibustion (n=15) for 10min
Number of subjects: 30
Study 20932583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ahmed glaucoma valve (AGV)
Number of subjects: 276
Study 20932583 — intervention group
Group type: COMPARATOR
Intervention: Baerveldt glaucoma implant (BGI)
Number of subjects: 276
Study 19363967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg, PO single dose)
Number of subjects: 31
Study 19363967 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tinted oil in clear capsule)
Number of subjects: 31
Study 17318070 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Number of subjects: 42
Study 17318070 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 42
Study 17318070 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 42
Study 15346539 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan pretreatment
Number of subjects: 32
Study 15346539 — intervention group
Group type: COMPARATOR
Intervention: CCK‐4
Number of subjects: 32
Study 11466983 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9862086 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (1.2 mg/kg, similar to a serving of ground coffee)
Number of subjects: 64
Study 9862086 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (1.2 mg/kg, 86 mg, 172 mg, 258 mg total across three doses)
Number of subjects: 64
Study 9862086 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no caffeine)
Number of subjects: 64
Study 7604149 — intervention group
Group type: EXPERIMENTAL
Intervention: IV yohimbine (0.4 mg/kg)
Number of subjects: 29
Study 7604149 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 29
Study 2405827 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy applied to the avascular retina in one eye or half the eyes depending on severity (18% of patients).
Number of subjects: 279
Study 2405827 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cryotherapy).
Number of subjects: 279
Study 7405249 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimeditiapramine (1 mg/kg body weight, single intravenous dose)
Number of subjects: 10
Study 30296475 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (Tissucol Duo) applied to one hemipelvis
Number of subjects: 74
Study 30296475 — intervention group
Group type: COMPARATOR
Intervention: Control group (hemipelvis not treated with fibrin sealant)
Number of subjects: 74
Study 30296475 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of lymphocele
Number of subjects: 74
Study 30296475 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean initial LC maximum diameter
Number of subjects: 74
Study 30296475 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean LC maximum diameter after one year
Number of subjects: 74
Study 28958851 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (3.0 mg, subcutaneous, escalated by 0.6 mg/day for 5 weeks, continued until week 16)
Number of subjects: 40
Study 28958851 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (3.0 mg, subcutaneous)
Number of subjects: 40
Study 28958851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 26264043 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-PART Self Care scale
Number of subjects: 996
Study 26264043 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-PART Domestic Life scale
Number of subjects: 996
Study 26264043 — intervention group
Group type: COMPARATOR
Intervention: FIM
Number of subjects: 996
Study 23785020 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (1st week 0.01 mg/day/kg, 2nd week 0.02 mg/day/kg, 3rd week 0.03 mg/day/kg)
Number of subjects: 8
Study 23785020 — intervention group
Group type: EXPERIMENTAL
Intervention: GH receptor antagonist (Pegvisomant) treatment (1st week 10 mg/day, last 2 weeks 15 mg/day)
Number of subjects: 8
Study 20495818 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaton tonometer
Number of subjects: 129
Study 20495818 — intervention group
Group type: COMPARATOR
Intervention: Corrected Goldmann applanation tonometry (c-GAT)
Number of subjects: 129
Study 18230945 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR) training for 25 min/week during weeks 2-8
Number of subjects: 83
Study 18230945 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group) including 2 days/week of exercise, education, and psychosocial support
Number of subjects: 83
Study 16698136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) tube feeding with low residual (Osmolite‐HN)
Number of subjects: 140
Study 16698136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) tube feeding with high-fat (Pulmocare)
Number of subjects: 140
Study 16698136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) tube feeding with glutamine-containing (AlitraQ)
Number of subjects: 140
Study 16698136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasojejunal (NJ) tube feeding with low residual (Osmolite‐HN)
Number of subjects: 140
Study 16698136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasojejunal (NJ) tube feeding with high-fat (Pulmocare)
Number of subjects: 140
Study 16698136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasojejunal (NJ) tube feeding with glutamine-containing (AlitraQ)
Number of subjects: 140
Study 16698136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) feeding
Number of subjects: 140
Study 16698136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasojejunal (NJ) feeding
Number of subjects: 140
Study 14666956 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured care with atorvastatin (10-80 mg/day, mean 23.7 mg/day)
Number of subjects: 313
Study 14666956 — intervention group
Group type: COMPARATOR
Intervention: Usual care (physician's standard of care)
Number of subjects: 313
Study 14666956 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured care with atorvastatin
Number of subjects: 313
Study 10960166 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion tests
Number of subjects: 24
Study 8838966 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ampicillin 1 g every 8 hours for 7 days
Number of subjects: 110
Study 8838966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 1283893 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride therapy for one week
Number of subjects: 0
Study 1283893 — intervention group
Group type: COMPARATOR
Intervention: Surgical castration
Number of subjects: 0
Study 1283893 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologically active DHT equivalent following finasteride
Number of subjects: 0
Study 3966370 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) alone
Number of subjects: 320
Study 3966370 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) combined with hydralazine, prazosin, oxprenolol, and propranolol
Number of subjects: 320
Study 31138273 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation project 'Don't forget the mouth!'
Number of subjects: 14
Study 31138273 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving oral health care as usual
Number of subjects: 14
Study 29985459 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led repeated prescription (NRP)
Number of subjects: 393
Study 29985459 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 393
Study 27061876 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of habitual physical activity
Number of subjects: 629
Study 25281504 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed circuit (HSC) training
Number of subjects: 21
Study 25281504 — intervention group
Group type: COMPARATOR
Intervention: Strength/hypertrophy (SH) training
Number of subjects: 21
Study 22889759 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib plus thalidomide (VT)
Number of subjects: 178
Study 22889759 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib plus prednisone (VP)
Number of subjects: 178
Study 19680697 — intervention group
Group type: EXPERIMENTAL
Intervention: Nano‐HA paste with papilla preservation flaps
Number of subjects: 14
Study 19680697 — intervention group
Group type: COMPARATOR
Intervention: Papilla preservation flaps alone
Number of subjects: 14
Study 17654295 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 291
Study 17654295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 17472838 — intervention group
Group type: EXPERIMENTAL
Intervention: supplemented very-low-protein diet (sVLPD)
Number of subjects: 112
Study 17472838 — intervention group
Group type: COMPARATOR
Intervention: dialysis
Number of subjects: 112
Study 15349539 — intervention group
Group type: EXPERIMENTAL
Intervention: Kock pouch
Number of subjects: 58
Study 15349539 — intervention group
Group type: EXPERIMENTAL
Intervention: Kock neobladder
Number of subjects: 58
Study 15349539 — intervention group
Group type: EXPERIMENTAL
Intervention: Mainz‐II pouch
Number of subjects: 58
Study 10786742 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. tenoxicam 20 mg
Number of subjects: 50
Study 10786742 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tenoxicam)
Number of subjects: 50
Study 9113635 — intervention group
Group type: EXPERIMENTAL
Intervention: High-AA diet (1.5 g/d)
Number of subjects: 10
Study 9113635 — intervention group
Group type: COMPARATOR
Intervention: Low-AA diet (basal diet)
Number of subjects: 10
Study 8368552 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine (5 mg)
Number of subjects: 84
Study 8368552 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (5 mg)
Number of subjects: 84
Study 8368552 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (5 mg)
Number of subjects: 84
Study 8368552 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 84
Study 3752420 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy with birch pollen extract (20 X 10(6) BU monthly, daily for seven consecutive days every month or once weekly)
Number of subjects: 24
Study 3752420 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy with birch pollen extract (more than 2 X 10(5) BU monthly)
Number of subjects: 24
Study 3752420 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy with birch pollen extract
Number of subjects: 24
Study 3752420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31394910 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga (twice a week for 8 weeks)
Number of subjects: 67
Study 31394910 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 67
Study 29541538 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS (2 mA)
Number of subjects: 15
Study 29541538 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 15
Study 27017151 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated patients
Number of subjects: 167
Study 27017151 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated patients
Number of subjects: 167
Study 27017151 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified by LDLR functionality
Number of subjects: 167
Study 24718821 — intervention group
Group type: COMPARATOR
Intervention: Best Supportive Care (BSC)
Number of subjects: 421
Study 24718821 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (<60 gy)
Number of subjects: 421
Study 24718821 — intervention group
Group type: COMPARATOR
Intervention: Higher doses of radiotherapy (>30 gy to <60 gy)
Number of subjects: 421
Study 23122434 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density foam wedge used on school chairs
Number of subjects: 185
Study 23122434 — intervention group
Group type: COMPARATOR
Intervention: Normal school seating (Control)
Number of subjects: 185
Study 19786525 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) intervention
Number of subjects: 84
Study 19786525 — intervention group
Group type: COMPARATOR
Intervention: Previous study using the same process measure (AIS) for smoking cessation
Number of subjects: 84
Study 17145164 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy (VRE)
Number of subjects: 0
Study 14981214 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of methylphenidate (0.5 mg/kg)
Number of subjects: 9
Study 14981214 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of methylphenidate (0.5 mg/kg)
Number of subjects: 9
Study 14981214 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of methylphenidate (1.0 mg/kg)
Number of subjects: 9
Study 14981214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 11182173 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril plus 25 mg i.v. of canreonate (1 mg/h for the 1st 72 h and then orally 25 mg/day)
Number of subjects: 55
Study 11182173 — intervention group
Group type: COMPARATOR
Intervention: Captopril and placebo
Number of subjects: 55
Study 9638313 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate (GS) at a daily dose of 1,500 mg for 4 weeks
Number of subjects: 178
Study 9638313 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (IBU) at a daily dose of 1,200 mg for 4 weeks
Number of subjects: 178
Study 8304303 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy for 1 wk plus omeprazole for 4 wk (Triple+OMP)
Number of subjects: 155
Study 8304303 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole alone for 4 wk (OMP)
Number of subjects: 155
Study 3054251 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxypropylmethylcellulose (HPMC) 2% solution
Number of subjects: 65
Study 3054251 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (control)
Number of subjects: 65
Study 31058716 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg daily)
Number of subjects: 135
Study 31058716 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (2 mg daily)
Number of subjects: 135
Study 31058716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 28842402 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioral treatment (FBT)
Number of subjects: 96
Study 28842402 — intervention group
Group type: COMPARATOR
Intervention: Attention-controlled information control (IC)
Number of subjects: 96
Study 26555348 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV3-HD
Number of subjects: 300
Study 23390069 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional antimony (IL Sb) 650 µg/mm² on days 1, 3, and 5
Number of subjects: 80
Study 23390069 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy on days 1 and 14
Number of subjects: 80
Study 23390069 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream daily for 20 days
Number of subjects: 80
Study 20920142 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC plus Tio (50/250 µg twice daily plus 18 µg once daily)
Number of subjects: 30
Study 20920142 — intervention group
Group type: COMPARATOR
Intervention: Tio alone (18 µg once daily)
Number of subjects: 30
Study 19686407 — intervention group
Group type: EXPERIMENTAL
Intervention: pantoprazole 40 mg, 4 mg/h infusion
Number of subjects: 61
Study 19686407 — intervention group
Group type: EXPERIMENTAL
Intervention: pantoprazole 80 mg bolus followed by 8 mg/h
Number of subjects: 61
Study 19686407 — intervention group
Group type: COMPARATOR
Intervention: pantoprazole 40 mg bolus injection every 24 h
Number of subjects: 61
Study 19686407 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori (−) group with continuous infusion
Number of subjects: 61
Study 19686407 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori (+) group with continuous infusion
Number of subjects: 61
Study 17908973 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspase-3 activity lower than the median in tumor tissue
Number of subjects: 117
Study 17908973 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspase-3 activity in preoperative biopsies
Number of subjects: 117
Study 17908973 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspase-3 activity lower than the median in tumor tissue (adjusted)
Number of subjects: 117
Study 14718459 — intervention group
Group type: EXPERIMENTAL
Intervention: Premixed 50% nitrous oxide and oxygen
Number of subjects: 105